公开(公告)号：US20230212126A1

公开(公告)日：2023-07-06

申请号：US18001074

申请日：2021-06-08

Applicant: UNIVERSITÄT ZÜRICH ,  ETH ZÜRICH

Inventor： Gisbert SCHNEIDER ,  Cyrill BRUNNER ,  Martin BAUMGARTNER ,  Karthiga Santhana KUMAR ,  Oliver ZERBE

IPC: C07D221/16 ,  A61P35/04

CPC classification number: C07D221/16 ,  A61P35/04

Abstract: The present invention relates to small-molecule inhibitors of the FRS2-FGFR interaction. The present invention relates the small-molecule inhibitors for use as a medicament and for use in cancer or metastasis treatment or prevention.

公开(公告)号：US20230211022A1

公开(公告)日：2023-07-06

申请号：US17810956

申请日：2022-07-06

Applicant: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. ,  Modulation Therapeutics, Inc. ,  Wake Forest University Health Sciences

Inventor： David MORSE ,  Robert GILLIES ,  Mark MCLAUGHLIN ,  Thaddeus WADAS ,  Hyun Joo KIL ,  Narges TAFRESHI

IPC: A61K51/08 ,  G01N33/574 ,  C07K14/705 ,  A61K38/08 ,  A61P35/04 ,  C07K7/06 ,  A61K38/00

CPC classification number: A61K51/088 ,  G01N33/5743 ,  C07K14/705 ,  A61K38/08 ,  A61P35/04 ,  C07K7/06 ,  A61K38/00

Abstract: The subject matter disclosed herein relates generally to cancer therapy and to anticancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target MC1R and their use in the treatment of cancer. Methods of screening for MC1R targeted agents are also disclosed.

公开(公告)号：US20230210971A1

公开(公告)日：2023-07-06

申请号：US17889715

申请日：2022-08-17

Applicant: University of Louisville Research Foundation, Inc.

Inventor： Huang-Ge Zhang

IPC: A61K39/00 ,  A61K9/00 ,  A61K31/05 ,  A61K31/513 ,  A61K33/243 ,  A61K31/203 ,  A61P35/00 ,  A61P35/04 ,  A61K31/12 ,  C12N15/113 ,  A61K31/704 ,  A61K9/127 ,  A61K39/39 ,  A61K31/475 ,  A61K38/12 ,  A61K31/337 ,  A61K31/353

CPC classification number: A61K39/0012 ,  A61K9/0056 ,  A61K31/05 ,  A61K31/513 ,  A61K33/243 ,  A61K31/203 ,  A61P35/00 ,  A61P35/04 ,  A61K31/12 ,  C12N15/1135 ,  A61K39/001102 ,  A61K31/704 ,  A61K9/1277 ,  A61K39/39 ,  A61K31/475 ,  A61K38/12 ,  A61K31/337 ,  A61K31/353 ,  A61K2039/55 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/531 ,  A61K2039/812 ,  A61K2039/6018

Abstract: Provided are compositions and methods for using the same. In some embodiments, the compositions include an EPELN encapsulating and/or having associated therewith an active agent and a plasma membrane derived from a tumor and/or cancer cell coating the EPELN. In some embodiments, the active agent is a therapeutic agent or an immune response modifier, and in some embodiments the plasma membrane has one or more tumor-associated and/or cancer-associated antigens. Also provided are methods for using the compositions for treating tumors and/or cancers, inducing anti-tumor and/or anti-cancer immune responses, activating antigen-presenting cells, targeting CD11c dendritic cells, and preventing or reducing metastasis.

公开(公告)号：US20230203202A1

公开(公告)日：2023-06-29

申请号：US18062453

申请日：2022-12-06

Applicant: Dragonfly Therapeutics, Inc.

Inventor： Mitchell Bigelow ,  Mark DeRose ,  Jinyan Du ,  Robin Friedman ,  Pyae P. Hein ,  Stuart William Hicks ,  Zong Sean Juo ,  Xinbi Li ,  Christopher Ryan Morgan

IPC: C07K16/46 ,  A61P35/04

CPC classification number: C07K16/468 ,  A61P35/04 ,  C07K2317/565 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/53 ,  C07K2317/31

Abstract: Multispecific binding proteins that bind NKG2D receptor, CD16, and 5T4 are described, as well as pharmaceutical compositions, formulations, and therapeutic methods of the multispecific binding proteins useful for the treatment of cancer.

公开(公告)号：US20230192833A1

公开(公告)日：2023-06-22

申请号：US17906627

申请日：2021-03-19

Applicant: CENTRE NATIONAL DE LA RECHERCHE (CNRS) ,  INSERM (institut National de la Sante et de la Recherche Medicale) ,  UNIVERSITE COTE D'AZUR

Inventor： Gilles PAGES ,  Renaud GREPIN ,  Aurore DUMOND

IPC: C07K16/22 ,  C12N15/63 ,  A61P35/04

CPC classification number: C07K16/22 ,  C12N15/63 ,  A61P35/04 ,  C07K2317/565 ,  C07K2317/24

Abstract: The invention relates to an isolated anti-vascular endothelial growth factor-C (VEGFC) antibody or a functional fragment thereof, said antibody comprising a heavy chain comprising at least one, preferentially at least two, preferentially three, of CDR-H1, CDR-H2 and CDR-H3 of amino acid sequences SEQ ID N° 6, 7 and 8 and a light chain comprising at least one, preferentially at least two, preferentially three of CDR-L1, CDR-L2 and CDR-L3 of amino acid sequences SEQ ID N° 9, 10 and 11, respectively.

公开(公告)号：US20230190805A1

公开(公告)日：2023-06-22

申请号：US17938311

申请日：2022-10-05

Applicant: Immatics Biotechnologies GmbH

Inventor： Jens HUKELMANN ,  Heiko SCHUSTER ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Frank SCHWOEBEL ,  Lena Katharina FREUDENMANN

IPC: A61K35/17 ,  G01N33/574 ,  C07K14/725 ,  A61P35/04 ,  A61P11/00

CPC classification number: A61K35/17 ,  G01N33/57492 ,  C07K14/7051 ,  A61P35/04 ,  A61P11/00 ,  C07K2317/565 ,  C07K2317/626 ,  C07K2317/622 ,  C07K2317/55

Abstract: A method of treating a metastatic lesion that presents a peptide containing SLLQHLIGL (SEQ ID NO: 310) on a cell surface, including selecting a patient having a metastatic lesion and administering to the patient a composition containing recombinant T lymphocytes or activated T lymphocytes that express a T cell receptor, or a functional fragment thereof, that is reactive with, or binds to, an MHC ligand containing SLLQHLIGL (SEQ ID NO: 310).

公开(公告)号：US20230190803A1

公开(公告)日：2023-06-22

申请号：US17924982

申请日：2021-05-13

Applicant: ADAPTIMMUNE LIMITED

Inventor： Dennis Robert WILLIAMS

IPC: A61K35/17 ,  A61P35/00 ,  A61K38/17 ,  A61P35/04 ,  A61P25/00 ,  A61P11/00

CPC classification number: A61K35/17 ,  A61K38/177 ,  A61K38/1774 ,  A61P11/00 ,  A61P25/00 ,  A61P35/00 ,  A61P35/04 ,  A61K2039/545

Abstract: The present invention relates to a method of treating, preventing or delaying the progression of cancer and/or tumour in a subject comprising administering to the subject a treatment regimen comprising an effective amount of modified immunoresponsive cells expressing or presenting a heterologous T-cell receptor (TCR) having the property of binding to MAGE A4

公开(公告)号：US20230172879A1

公开(公告)日：2023-06-08

申请号：US17921060

申请日：2021-04-23

Applicant: LUNELLA BIOTECH, INC.

Inventor： Michael P. LISANTI ,  Federica SOTGIA

IPC: A61K31/137 ,  A61K31/55 ,  A61K31/40 ,  A61K31/551 ,  A61K31/4439 ,  A61K31/438 ,  A61K31/519 ,  A61K31/65 ,  A61K31/7048 ,  A61K31/7052 ,  A61K31/122 ,  A61K31/4745 ,  A61K31/44 ,  A61K31/167 ,  A61K31/4375 ,  A61K31/36 ,  A61K31/4706 ,  A61P35/04

CPC classification number: A61K31/137 ,  A61K31/55 ,  A61K31/40 ,  A61K31/551 ,  A61K31/4439 ,  A61K31/438 ,  A61K31/519 ,  A61K31/65 ,  A61K31/7048 ,  A61K31/7052 ,  A61K31/122 ,  A61K31/4745 ,  A61K31/44 ,  A61K31/167 ,  A61K31/4375 ,  A61K31/36 ,  A61K31/4706 ,  A61P35/04

Abstract: Cancer stem cells are responsible for tumor recurrence, distant metastasis and drug-resistance, in the vast majority of cancer patients. There exists an urgent need to identify new mitochondrial inhibitor drugs that can target and eradicate CSCs, and companion diagnostics to identify candidates for mitochondrial inhibition therapy. In 3D mammospheres, 25 mitochondrial-related proteins were over 100-fold over-expressed in a large collection of transcriptional profiling data from ER(+) breast cancer patients. These 25 proteins may be used to derive short gene signatures to predict the likelihood of distant metastasis and tumor recurrence. For example, the 4-gene signature of ACLY, VDAC3, HADH2, and COX6B1 may be used for predicting the likelihood of distant metastasis, with a hazard ratio of 1.91-fold (P=2.2e−08). A pharmaceutically effective amount of a mitochondrial inhibitor may be administered to a candidate having elevated expression of the genes in a gene signature. Five example mitochondrial inhibitors showed preferential and selective inhibition of tumor cell metastasis, without causing significant toxicity. Mechanistically, all five mitochondrial inhibitors have been previously shown to induce ATP-depletion in cancer cells. Gene signatures composed of 6-9 large mitochondrial ribosomal proteins also show prognostic value in predicting distant metastasis, tumor recurrence, and Tamoxifen resistance, in both ER(+) and ER(−) breast cancer patients. The disclosed gene signatures may be used as companion diagnostics to assess which patients may benefit most from mitochondrial inhibition therapy.

公开(公告)号：US11667726B2

公开(公告)日：2023-06-06

申请号：US16943320

申请日：2020-07-30

Applicant: BROWN UNIVERSITY

Inventor： Jack A. Elias ,  Chun Geun Lee ,  Chuan Hua He ,  Bing Ma ,  Suchitra Kamle ,  Chang-Min Lee

IPC: C07K16/40 ,  A61P35/04 ,  A61K45/06 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K16/40 ,  A61K45/06 ,  A61P35/04 ,  C07K16/2803 ,  C07K16/2839 ,  A61K2039/505 ,  A61K2300/00 ,  C07K2317/34 ,  C07K2317/73 ,  C07K2317/76

Abstract: It is demonstrated herein that inhibitors of immune checkpoints and CHI3L1 are synergistic. Accordingly, described herein are methods and compositions relating to combinatorial therapies for cancer, e.g., comprising an inhibitor of CHI3L1; and an inhibitor of an immune checkpoint protein. In some embodiments, the CHI3L1 inhibitor can be an antibody or antibody reagent as described herein.

公开(公告)号：US11667604B2

公开(公告)日：2023-06-06

申请号：US17627965

申请日：2020-07-14

Applicant: SHANGHAI MODERN PHARMACEUTICAL ENGINEERING RESEARCH CENTER CO., LTD. ,  SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY

Inventor： Jun He ,  Zhefeng Wang ,  Yuezhu Zhao ,  Yani Yang ,  Qinghui Fu ,  Wei Bian ,  Yuan Zhao ,  Chen Ge ,  Yue Zhang ,  Bing Yi ,  Minghao Niu ,  Jiuhui Zhang

IPC: C07C309/18 ,  A61K9/107 ,  A61K31/337 ,  A61K47/20 ,  A61P35/04

CPC classification number: C07C309/18 ,  A61K9/1075 ,  A61K31/337 ,  A61K47/20 ,  A61P35/04

Abstract: A phenyl-containing compound, an intermediate thereof, a preparation method therefor and an application thereof. Provided is a compound represented by formula I or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4 and R5 are independently hydrogen, C1-C6 alkyl, C1-C6 alkoxy or C(═O)OR8; where R8 is C1-C4 alkyl; R6 is (II), (III) or (IV); and R7 is —OH, —NH2, —NHCH3, —N(CH3)2 or C1-4 alkoxy. The compound has a low critical micelle concentration (CMC) and good dilution resistance and is capable of enclosing an insoluble drug to form a small-molecule micelle having a high drug loading capacity and good stability.